Skip to main content
Premium Trial:

Request an Annual Quote

Senomyx Chairman, CSO Steps Down, New Appointments Made

NEW YORK, May 22 – Senomyx said Tuesday that it had appointed Paul Grayson chairman of the board and promoted Mark Zoller to the position of chief scientific officer, continuing a management reshuffle that has taken place over the past month.

Grayson, who is CEO of the company, and Zoller, who is vice president of research, will be replacing Lubert Stryer in his roles as chairman and CSO.

Stryer is returning to Stanford University following a two-year sabbatical at Senomyx.

"All of us at Senomyx are indebted to Dr. Stryer for his overwhelming contributions to the company," Grayson said in a statement. "His work included not only founding the company but also providing vision and leadership.”

Grayson was also a founder of Senomyx, a La Jolla, Calif.-based developer of flavor and fragrance molecules designed to be used in consumer products.

Earlier this month, Senomyx announced that Saiid Zarrabian, who resigned as chief operating officer at Pharmacopeia in December, had been appointed president and COO of Senomyx, replacing Grayson in his previous role as president.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.